New insider activity at Artivion ( (AORT) ) has taken place on August 19, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
President & CEO James Mackin has recently sold 12,500 shares of Artivion stock, amounting to a significant transaction valued at $528,875.
Recent Updates on AORT stock
Artivion has seen significant developments recently, with multiple analysts raising their price targets for the company’s stock. The upgrades are primarily driven by Artivion’s strong Q2 2025 earnings report, which highlighted a 14.6% constant currency revenue growth, significantly up from 3.6% in Q1. This growth was fueled by strong performances in the On-X and stent graft product lines. Additionally, Artivion’s successful product launches, such as AMDS, and improved financial stability through reduced net leverage have contributed to a positive market outlook. The company’s strategic initiatives, including progress in its pipeline with products like NEXUS and Arcevo, further support the optimistic future guidance. Despite some challenges, such as costs from a cybersecurity incident and delays in the China BioGlue launch, the overall sentiment remains positive, reflected in the raised revenue and EBITDA guidance for 2025.
Spark’s Take on AORT Stock
According to Spark, TipRanks’ AI Analyst, AORT is a Neutral.
Artivion’s overall score is driven by strong earnings call results and positive corporate events, but is weighed down by financial performance challenges and lack of technical analysis data.
To see Spark’s full report on AORT stock, click here.
More about Artivion
YTD Price Performance: 52.60%
Average Trading Volume: 407,192
Technical Sentiment Signal: Buy
Current Market Cap: $2.02B